Stem Cells Therapies in Neurodegenerative Diseases Lab, Research Center "Principe Felipe", Valencia, Spain.
National Stem Cell Bank-Valencia Node, Biomolecular and Bioinformatics Resources Platform PRB2, ISCIII, Research Center "Principe Felipe", Valencia, Spain.
Stem Cells. 2018 Apr;36(4):474-481. doi: 10.1002/stem.2783. Epub 2018 Feb 7.
Hereditary retinal dystrophies, specifically retinitis pigmentosa (RP) are clinically and genetically heterogeneous diseases affecting primarily retinal cells and retinal pigment epithelial cells with blindness as a final outcome. Understanding the pathogenicity behind these diseases has been largely precluded by the unavailability of affected tissue from patients, large genetic heterogeneity and animal models that do not faithfully represent some human diseases. A landmark discovery of human induced pluripotent stem cells (hiPSCs) permitted the derivation of patient-specific cells. These cells have unlimited self-renewing capacity and the ability to differentiate into RP-affected cell types, allowing the studies of disease mechanism, drug discovery, and cell replacement therapies, both as individual cell types and organoid cultures. Together with precise genome editing, the patient specific hiPSC technology offers novel strategies for targeting the pathogenic mutations and design therapies toward retinal dystrophies. This study summarizes current hiPSC-based RP models and highlights key achievements and challenges of these cellular models, as well as questions that still remain unanswered. Stem Cells 2018;36:474-481.
遗传性视网膜病变,特别是色素性视网膜炎(RP),是一种主要影响视网膜细胞和视网膜色素上皮细胞的临床和遗传异质性疾病,最终导致失明。由于无法从患者身上获得受影响的组织、遗传异质性大以及动物模型不能真实地代表某些人类疾病,这些疾病的发病机制在很大程度上仍未被了解。人类诱导多能干细胞(hiPSC)的一项里程碑式发现使得能够获得患者特异性细胞。这些细胞具有无限的自我更新能力,并能够分化为受 RP 影响的细胞类型,从而可以研究疾病机制、药物发现和细胞替代疗法,无论是作为单个细胞类型还是类器官培养。与精确的基因组编辑相结合,患者特异性 hiPSC 技术为靶向致病性突变和针对视网膜病变设计治疗方法提供了新的策略。本研究总结了基于 hiPSC 的 RP 模型,并强调了这些细胞模型的关键成就和挑战,以及仍然存在的未解决的问题。干细胞 2018;36:474-481.